305-33-9
305-33-9
Chemical Structure
Iproniazid phosphate
- CAS No.: 305-33-9
- Formula:C9H16N3O5P
- Molecular Weight:277.21
IUPAC Name: N'-isopropylisonicotinohydrazide phosphate
InChIKey: YPDVTKJXVHYWFY-UHFFFAOYSA-N
SMILES: O=C(C1=CC=NC=C1)NNC(C)C.O=P(O)(O)O
Biological Activity: Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Iproniazid phosphate | 99.92% | Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Iproniazid phosphate (Standard) | ≥98% | Iproniazid (phosphate) (Standard) is the analytical standard of Iproniazid phosphate (HY-B0886). This product is intended for research and analytical applications. Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Procarbazine Hydrochloride | 99.66% | Procarbazine Hydrochloride is an orally active alkylating agent, with anticancer activity. Procarbazine Hydrochloride can be used in Hodgkin's disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Procarbazine | Procarbazine is an orally active alkylating agent, with anticancer activity. Procarbazine can be used in Hodgkin's disease research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anti-inflammatory agent 11 | Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PluriSIn 1 | 99.72% | PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nialamide | 96.29% | Nialamide is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide inhibits MAO and regulates ROS production. Nialamide induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nialamide hydrochloride | Nialamide hydrochloride is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide hydrochloride inhibits MAO and regulates ROS production. Nialamide hydrochloride induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide hydrochloride can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N'-(Pyridin-4-ylmethylene)isonicotinohydrazide | ||||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N,N'-(ethane-1,2-diyl)diisonicotinamide | N,N'-(ethane-1,2-diyl)diisonicotinamide is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salinazid | 99.62% | Salinazid is an antituberculous compound. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N'-Isonicotinoylisonicotinohydrazide | N'-Isonicotinoylisonicotinohydrazide (Compound 7, 1,2-Diisonicotinoylhydrazine) is a competitive inhibitor (IC50=5-30 μM) of bacterial heme oxygenase (HO). N'-Isonicotinoylisonicotinohydrazide inhibits iron release and bacterial iron acquisition. N'-Isonicotinoylisonicotinohydrazide exhibits selective activity against HO enzymes from Pseudomonas aeruginosa and Neisseria meningitidis. N'-Isonicotinoylisonicotinohydrazide is promising for research of multidrug-resistant Gram-negative bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fagervall I, et al. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochemical pharmacology 35 (8): 1381–1387
- [2]. Watabe M, et al. Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther. 2007 Nov;323(2):499-507. [Content Brief]
- [3]. Dodson AM, et al. Serotonin uptake and metabolism by cultured guinea pig airway smooth muscle cells. Pulm Pharmacol Ther. 2004;17(1):19-25. [Content Brief]
- [4]. De Oliveira LF, et al. Effects of 5-hydroxytryptophan, iproniazid and p-chlorophenylalanine on lidocaine seizure threshold of mice. Eur J Pharmacol. 1974 Nov;29(1):5-9. [Content Brief]
- [5]. Nelson SD, et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther. 1978 Sep;206(3):574-85. [Content Brief]
- [6]. SETNIKAR I V O, et al. Retardation of sexual development in female rats due to iproniazid treatment. Endocrinology, 1960, 67(4): 511-520.
- [7]. Huang J T, et al. The effect of pretreatment with iproniazid on the behavioral activities of β-phenylethylamine in rats. Psychopharmacologia, 1974, 35(1): 77-81.
